AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets.
By delivering exceptional detection levels (<0.005% LOD), AlphaLiquid® Detect provides clinically actionable information for relapse monitoring and adjuvant therapy guidance with a significant lead time over conventional imaging diagnostics.
|Tumor tissue sequencing
Targeted hybrid capture NGS based on proprietary HQS™ technology
|Tissue : FFPE (10μm x 10 sections) or FF
Blood : >20mL of whole blood
|Customized panel of up to 1,000 targets
|SNVs and Indels
|Limit of Detection
|0.005% ~ 0.0005% ctDNA fraction